AstraZeneca's oral GLP-1 pill shows weight-loss results comparable to Ozempic and Wegovy — what does it mean for Canadian access?

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

AstraZeneca's investigational oral GLP-1 receptor agonist produced weight-loss results in a phase-2 trial that the company described as comparable to injectable semaglutide (sold in Canada as Ozempic for type 2 diabetes and Wegovy for chronic weight management), according to a June 8, 2026 report by AFP carried by CTV News. The drug has not been submitted to Health Canada for review, and no Canadian approval timeline has been announced. For a Canadian patient currently navigating the cost and supply problems that have plagued injectable GLP-1 drugs since 2022, this trial result is genuinely interesting — but it does not change what is available at a pharmacy today.

The trial data comes from an early-stage study. AstraZeneca has not yet published full peer-reviewed results, and the company has not confirmed when or whether it will file with Health Canada or the US Food and Drug Administration (FDA). GLP-1 receptor agonists are a class of drugs that mimic the gut hormone glucagon-like peptide-1, slowing gastric emptying and reducing appetite. The injectable members of this class, semaglutide and liraglutide (sold in Canada as Victoza and Saxenda), are already approved by Health Canada. An oral version of semaglutide, sold as Rybelsus, is also Health Canada-approved for type 2 diabetes — though not for weight management. AstraZeneca's candidate is a chemically distinct molecule, not an oral reformulation of semaglutide.

What this means in Canada

Health Canada has not received, reviewed, or approved AstraZeneca's oral GLP-1 candidate. The drug is not available in Canadian pharmacies and has no Drug Identification Number (DIN). Any Canadian patient who sees this drug marketed online or through cross-border channels should be aware it has no Health Canada authorization.

For comparison, Wegovy (semaglutide 2.4 mg injection) received Health Canada approval in November 2021 but faced severe and prolonged supply shortages that limited real-world access for years afterward. Provincial pharmacare coverage for GLP-1 drugs for obesity remains inconsistent across Canada. Ontario's OHIP does not cover Wegovy for weight management. Quebec's RAMQ covers semaglutide only under specific diabetes criteria. British Columbia's PharmaCare and Alberta's AHCIP have similarly narrow coverage windows for the obesity indication. Canada's national pharmacare framework, still being implemented as of mid-2026, has not yet listed GLP-1 drugs for obesity among its initial priority medications.

The SOGC (Society of Obstetricians and Gynaecologists of Canada) has not issued a position statement on oral GLP-1 drugs. The Obesity Canada clinical practice guidelines, last updated in 2020, support pharmacotherapy for obesity but predate the current generation of high-efficacy GLP-1 agents and do not address oral formulations.

Canadian telehealth platforms including Felix, Cleo, and Science & Humans (scienceandhumans.com) currently facilitate access to Health Canada-approved injectable GLP-1 drugs where clinically appropriate, but none can prescribe or dispense a drug that has not received a Canadian DIN. US-based platforms such as Hone Health and Calibrate are not available to Canadian patients and cannot legally prescribe into Canada.

What changed

The headline finding is that an oral pill produced weight loss in a range that, in early data, approaches what injectable GLP-1 drugs achieve. That matters because injection-based delivery is a real barrier for some patients: needle aversion, storage requirements (most injectables need refrigeration), and the visible nature of self-injection in shared spaces. A pill that matched injectable efficacy would remove those barriers.

The existing oral semaglutide product, Rybelsus (approved by Health Canada for type 2 diabetes), requires strict fasting conditions before dosing and delivers a lower systemic dose than the injectable form. It has not shown the same magnitude of weight loss as Wegovy in head-to-head comparisons. AstraZeneca's candidate uses a different absorption mechanism, which the company says may allow more flexible dosing, though that claim has not been independently validated in published peer-reviewed data as of this writing.

The Obesity Society and the Endocrine Society (US) have both noted in recent guidance that oral GLP-1 formulations with improved bioavailability are an active area of development, but neither body has reviewed AstraZeneca's specific compound.

What Canadian patients should know

If you are currently using or considering an injectable GLP-1 drug in Canada, this trial result does not change your options today. Ozempic (semaglutide 0.5 mg to 2 mg, for type 2 diabetes) and Wegovy (semaglutide 2.4 mg, for chronic weight management) remain the highest-efficacy Health Canada-approved options in this class. Liraglutide (Saxenda) is also approved for weight management.

Cost is a real issue. Wegovy runs approximately CAD $350 to $450 per month out of pocket in most provinces without private insurance coverage. Ozempic, used off-label for weight loss, is somewhat less expensive but supply has been intermittently restricted by Health Canada's drug shortage registry.

If AstraZeneca's oral drug eventually reaches a Canadian regulatory submission, the review process at Health Canada typically takes 12 to 18 months for a standard review, longer if the agency requests additional data. After approval, provincial formulary listing decisions add further time, often one to three years, before a drug becomes covered under provincial pharmacare plans. Patients in provinces with active pharmacare expansion, including those covered under the federal pharmacare framework for diabetes drugs, may see faster access once a listing decision is made — but that is speculative at this stage.

Patients with type 2 diabetes who are also managing weight should speak with their prescriber about currently approved options. Patients seeking weight management without a diabetes diagnosis face narrower coverage options and should ask specifically about their provincial formulary before assuming any GLP-1 drug will be covered.

Limitations and open questions

The trial data reported by AFP and CTV News has not been published in a peer-reviewed journal as of June 10, 2026. Conference presentations and company press releases are not the same as full clinical trial publications, and the history of obesity pharmacology includes several drugs that looked promising in early trials and failed in larger phase-3 studies or post-market surveillance.

Key questions that remain unanswered: What was the trial's sample size and duration? How does the drug's side-effect profile compare to injectable semaglutide, which commonly causes nausea, vomiting, and in rare cases more serious gastrointestinal events? What dose is required, and does it carry the same cardiovascular benefit signal that has been demonstrated for injectable semaglutide in the SELECT trial (published in the New England Journal of Medicine in 2023)? Does the oral formulation maintain efficacy across different body weight ranges?

Health Canada has not issued any guidance on this compound. The SOGC has not commented. The CMAJ (Canadian Medical Association Journal) has not published an analysis. Until phase-3 data are peer-reviewed and a regulatory submission is filed, the clinical picture is incomplete.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.